Eli Lilly's Zepbound weight loss drug reduces heart failure risks in late-stage trial

From NBC Universal: 2024-08-01 09:44:14

Eli Lilly’s Zepbound weight loss drug shows benefits for patients with heart failure and obesity in late-stage trial data. Patients were 38% less likely to be hospitalized or die from heart complications. Eli Lilly plans to submit results to regulators later this year. Shares of Eli Lilly rose more than 3% on the news.

Zepbound also improved heart failure symptoms and physical limitations, according to the study. Approximately 6.7 million adults in the U.S. have heart failure. Eli Lilly estimates HFpEF accounts for almost half of all heart failure cases, with nearly 60% of patients also having obesity. Common side effects of Zepbound were gastrointestinal.

Novo Nordisk, a competitor in the GLP-1 market, submitted an application for its weight loss drug, Wegovy, to treat patients with HFpEF. The FDA approved Wegovy for reducing serious heart complications. Both Novo Nordisk and Eli Lilly are studying their drugs in patients with chronic kidney disease and fatty liver disease.



Read more at NBC Universal: Eli Lilly weight loss drug Zepbound cuts heart failure risks in study